CHRONOGEN AND INPHARZAM ENTER AGREEMENT

Chronogen (Montreal, Canada), a drug discovery company developing novel therapeutics to treat age-related diseases and Inpharzam Ricerche (Taverne, Switzerland), subsidiary of the international chemicals and pharmaceutical company, Zambon Group S.p.A, jointly announced today that they have entered into an R&D collaboration agreement with the aim of identifying small molecules for the treatment of cardiovascular and metabolic diseases induced by oxidative damage and/or lipids disorders.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20497520&full=1)